Plain-English translation of NCT05645107 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called ®, which is an immune protein designed to help prevent serious bacterial infections in people with certain blood cancers (chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma) whose immune systems are weakened. Half of participants will receive the medication along with their standard cancer treatment, while the other half will receive a placebo (a dummy infusion) along with their standard cancer treatment. The study will last about one year and will measure whether the medication reduces how often participants get serious infections.
People with certain blood cancers often develop weak immune systems that make them unable to fight off infections effectively, even with their cancer treatment. This trial exists to see whether this new immune protein medication can help prevent these dangerous infections and improve quality of life.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive either the new medication or a placebo, given as an injection under the skin. You'll start with five daily infusions in the first week, then receive infusions every two weeks for about one year. Throughout the study, you'll continue your regular cancer treatments and have regular visits to check for infections, monitor your health, and track how well the medication is working.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States